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Abstract. The aim of the present study was to examine 
the expression of phosphoglycerate mutase 1 (PGAM1) in 
astrocytomas, and to investigate its role in the progression of 
astrocytomas. The expression of PGAM1 mRNA in rat C6 
glioma cells and normal astrocytes was determined using 
the reverse transcription-semi-quantitative polymerase chain 
reaction, and immunohistochemistry was used to detect the 
expression of PGAM1 protein in human astrocytomas and 
adjacent brain tissue. These data suggested that the expression 
of PGAM1 in rat C6 glioma cells was significantly increased 
compared with that of normal astrocytes (P<0.05), and the 
expression of PGAM1 protein in human astrocytoma tissue 
was significantly increased compared with that of the brain 
tissue surrounding the tumor (P<0.05). In addition, PGAM1 
protein was more frequently expressed in high-grade astro-
cytomas compared with low-grade astrocytomas. These data 
indicate that the expression of PGAM1 is increased in C6 cells 
and human astrocytomas, and PGAM1 is probably involved in 
the tumorigenesis and progression of glioma, which may be a 
potential target for glioma treatment.
Introduction
Gliomas are the most common primary malignant brain tumor 
with poor clinical outcome and account for 40-50% of primary 
intracranial neoplasms (1). The etiology and pathogenesis of 
gliomas remain to be elucidated. Despite the advances in ther-
apeutic approaches, treatment offers limited aid in prolonging 
survival (2). In view of the overall poor outcome with current 
therapies, a better understanding of glioma etiology is crucial 
for future development of more effective treatments to cure 
this rapidly progressing disease.
It has been demonstrated that the growth of cancer 
cells is primarily dependent on the glycolysis pathway (3). 
Phosphoglycerate mutase 1 (PGAM1) catalyzes the conversion 
of 3-phosphoglycerate (3-PG) to 2-phosphoglycerate (2-PG) to 
release energy and is one of the key enzymes in the glycolytic 
pathway. A previous study by Ramanathan et al (3) suggested 
that knocking out the glycolysis pathway may cause extreme 
damage to tumor cells. However, the role of PGAM1 in glioma 
is poorly investigated.
In the present study, PGAM1 mRNA expression in rat 
C6 glioma cells and astrocytes, and the protein expression 
in human infiltrating astrocytomas of different World Health 
Organization (WHO) grades (4) and peritumoral brain tissue 
were investigated, and the role of PGAM1 in glioma prolifera-
tion and progression was discussed.
Materials and methods
Animals and cells. A total of 40 male adult Sprague-Dawley 
rats about 3 months old, weight 250±30 g, were provided by 
the Experimental Animal Center of Shandong University 
(Jinan, China), and maintained in a climate-controlled and 
sound isolated room (21˚C) under a 12:12‑h light:dark cycle, 
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with 40-60% relative humidity and fed on laboratory chow 
and water ad libitum. Following 1-week acclimation, rats were 
sacrificed by intraperitoneal injection of sodium pentobarbital 
(45 mg/kg). Brain tissue was obtained for the experiments. 
The glioma C6 cell lines were purchased from the Institute of 
Biochemistry and Cell Biology, Chinese Academy of Sciences 
(Shanghai, China). Ethical approval was provided by the Ethics 
Committee of Qilu Hospital (Shandong, China).
Patient specimens. A total of 102 cases of astrocytomas treated 
in the Department of Neurosurgery, Shandong Cancer Hospital 
(Jinan, China) and Qilu Hospital of Shandong University 
(Jinan, China) between December 2011 and June 2013 were 
collected (59 males and 43 females; median age, 47 years; age 
range, 28‑66 years). According to WHO 2007 criteria, 38 cases 
were WHO grade II, 30 cases were WHO grade III and 34 were 
WHO grade IV (4). A total of 11 cases of peritumoral brain 
tissue were also collected. No patients had ever received 
chemotherapy or radiation therapy prior to surgery.
Reagents. TRIzol was purchased from Invitrogen (Thermo 
Fisher Scientific, Inc. Waltham, MA, USA). Chloroform, 
isopropanol and diethyl pyrocarbonate-treated water were 
purchased from Shanghai Sangon Biological Engineering 
Technology Services Ltd. (Shanghai, China). Ethidium bromide 
(EB) was purchased from Sigma‑Aldrich; Merck KGaA 
(Darmstadt, Germany); the reverse transcription‑polymerase 
chain reaction (RT-PCR) PrimeScript™ RT reagent kit (cat 
no. RR037A) was purchased from Takara Biotechnology Co., 
Ltd. (Dalian, China), deoxynucleotide triphosphates (dNTPs), 
Taq DNA polymerase and CASsuper 7Kb DNA Marker were 
purchased from Promega Corporation (Madison, WI, USA). 
Poly-L-lysine, immunohistochemical hypersensitivity kit, goat 
anti-human PGAM1 antibody (sc-376638), 3,3'-diaminoben-
zidine (DAB) dye (sc-24982) and antibody dilutions (sc-2023) 
were purchased from Santa Cruz Biotechnology, Inc. (Dallas, 
TX, USA).
Culture, passage and identification of astrocytes. Bilateral 
brain cortex tissue (~0.5 g) from 1-week-old SD rats was 
collected and washed with Ca2+/Mg2+-free Hanks solution 
(sc‑391061; Santa Cruz Biotechnology, Inc.) twice. The brain 
tissue was shredded and kept at room temperature for 10 min 
with trypsin (sc‑391055; 1:250; Santa Cruz Biotechnology, 
Inc.). The resulting brain tissue was transferred into the 
centrifuge tube and centrifuged at 1,000 x g for 3 min at 
4˚C for cell separation. Cell suspension was collected and 
transferred into a new tube and centrifuged at 1,500 x g for 
5 min at 4˚C. The second cell suspension was seeded into a 
culture flask that was previously coated (4˚C, overnight) with 
poly‑L‑lysine (sc‑286689; 0.1%; Santa Cruz Biotechnology, 
Inc.). Cells were cultured with Dulbecco's modified Eagle's 
medium (DMEM)/Ham's F12 with 15% fetal bovine serum 
(FBS; 16250086; Thermo Fisher Scientific, Inc.) at 37˚C in 
a 5% CO2 incubator. Finally, astrocytes were identified with 
glial fibrillary acidic protein (GFAP; sc‑33673; Santa Cruz 
Biotechnology, Inc.) immunofluorescence (5).
The immunostaining steps were as follows: Coverslips 
with their attached cells were removed from the culture 
medium and washed three times in phosphate buffered saline 
(PBS; sc‑286634; Santa Cruz Biotechnology, Inc.) before 
being fixed in 4% paraformaldehyde (sc‑281692; Santa Cruz 
Biotechnology, Inc.) for 1 h at room temperature. The cover-
slips were then washed three times in cold PBS (5 min each). 
Prior to staining, cells were permeabilised in PBS containing 
0.01% Triton for 10 min at room temperature and then washed 
three times in cold PBS (3 min each). The coverslips were 
blocked with 10% normal goat serum for 1 h at 37˚C. Each 
coverslip was incubated with 20 µl mouse anti-GFAP primary 
antibody (cat no. sc‑33673; Santa Cruz Biotechnology, Inc.) 
1:200 at 4˚C overnight. Negative controls were incubated 
identically but without primary antibody. Coverslips were 
then washed three times in PBS, then incubated with a goat 
anti‑rabbit secondary antibody conjugated to FITC (sc‑2010; 
1:100; Santa Cruz Biotechnology, Inc.) for 30 min at room 
temperature and washed three times in cold PBS 5 min each. 
Then the coverslips were incubated with 20 µl DAPI (sc‑3598; 
Santa Cruz Biotechnology, Inc.) for 5 min at room temperature 
in the dark. Images were captured using a confocal microscope 
(PerkinElmer, Inc., Waltham, MA, USA) at a wavelength of 
520 nm.
Culture of C6 glioma cells. C6 glioma cells were cultured in 
DMEM/Ham's F12 containing 15% FBS at 37˚C in a 5% CO2 
incubator. Following cells reaching exponential phase, they 
were subcultured into two culture flasks.
Total RNA extraction and detection of PGAM1 mRNA expres-
sion in rat astrocytes and C6 glioma cells
Extraction of total RNA from C6 and astrocytes. Once the 
cultured cells were confluent in the culture flasks, the culture 
medium was removed and cells were washed for 30 sec with 
PBS twice. Total RNA was extracted using a TRIzol RNA 
extraction kit (Thermo Fisher Scientific, Inc.) according to the 
manufacturer's protocol. RNA concentration and quality were 
determined using a NanoDrop ND-1000 spectrophotometer 
(A260/A280 values were 1.80‑2.0; Thermo Fisher Scientific, Inc.) 
and gel electrophoresis.
Reverse transcription (first‑strand cDNA synthesis). A total 
of 2 µg total RNA, 2.0 µl 10 µmol/l oligo dNTPs, 2.0 µl 10X 
PCR buffer, 2.0 µl 5 µmol/l dNTPmix, 1.0 µl dNTP mixture, 
RNasin® Ribonuclease Inhibitor (4 U/µl; Invitrogen; Thermo 
Fisher Scientific, Inc.), and an appropriate amount of diethyl 
pyrocarbonate-treated water was added to a total volume 
of 20 µl, and thenplaced into a 0.5 ml Eppendorf tube. The 
mixture was incubated at 37˚C for 60 min, and the reaction 
was stopped by heating at 70˚C for 15 min. Then, the reac-
tion tube was transferred to ice, and 20 µl Tris-EDTA buffer 
(Invitrogen; Thermo Fisher Scientific, Inc.) was added.
PCR and electrophoresis of PCR products. PCR primers 
were synthesized by Beyotime Institute of Biotechnology 
(Shanghai, China). The PGAM1 forward primer sequence was 
5'-CCT CCT GTG AGA GCC TGA AG-3' (nt452-nt471) and the 
PGAM1 reverse primer sequence was 5'-CTT CTT CAC CTT 
GCC CTG AG-3' (nt762-nt743). β-actin was used as an internal 
reference. A total of 2 µl cDNA, 2.5 µl 10X PCR buffer, 
1.5 µl MgCl2, 1.0 µl dNTP mixture (2 mmol/l), 0.5 µl forward 
primer (10 µmol/l), 0.5 µl reverse primer (10 µmol/l), 0.5 µl 
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Taq enzyme (2 U/µl) and 16.5 µl double-distilled water were 
added into a 0.2 ml Eppendorf PCR tube on ice. Following 
PCR (pre‑denaturation at 94˚C for 7 min, denaturation at 94˚C 
for 30 sec, annealing at 56˚C for 30 sec, extension at 72˚C for 
30 sec), 5 µl PCR product was analyzed on 1.5% agarose gel 
electrophoresis at 100 V for 15 min. The image was captured 
under UV light (WFH‑204A; JK Technology, Shanghai, 
China). The intensity of these bands was semi‑quantified using 
an imaging analyzer (ImageJ version 1.48; National Institutes 
of Health, Bethesda, MD, USA).
Immunohistochemistry on paraffin‑embedded tissue sections. 
Sections of paraffin tissue 5‑µm thick were deparaffinized by 
using xylene and rehydrated through a graded alcohol series 
to water. The dewaxed slides underwent antigen retrieval in 
citrate buffer (Beyotime Institute of Biotechnology, Shanghai, 
China) for 30 min by microwaving (Midea, Guangdong, 
China) and then cooled to room temperature. Peroxidase 
blocking solution (Beyotime Institute of Biotechnology, 
Shanghai, China) was used to block endogenous peroxidase 
activity at room temperature for 10 min. Tissue sections 
were incubated with anti-PGAM1 antibody (1:100 dilu-
tion) at 4˚C overnight, and then incubated with biotinylated 
rabbit anti‑Goat antibody (1:1,000; cat no. sc‑2768; Santa 
Cruz Biotechnology, Inc.) at room temperature for 10 min. 
A drop of streptavidin-biotin-peroxidase solution Beyotime 
Institute of Biotechnology, Shanghai, China was added onto 
each section and incubated at room temperature for 10 min. 
Tissue sections were incubated with freshly prepared DAB 
chromogenic reagent for 1-2 min at room temperature, then 
counterstained with hematoxylin (1 µM; Beyotime Institute 
of Biotechnology, Shanghai, China) for 3 min at room 
temperature. Ten low power fields (magnification, x100) 
were selected randomly and immunostaining was detected at 
a high power (magnification, x400) using a light microscope 
(BX43; Olympus Corporation, Tokyo, Japan). The immuno-
histochemical stain results were divided into negative (<10% 
of cells with marked cytoplasmic staining), positive (10-70% 
cells with marked cytoplasmic staining) and strongly posi-
tive (>70% cells with marked cytoplasmic staining). Positive 
and strongly positive results were statistically counted as 
positive.
Statistical analysis. Data are expressed as mean ± standard 
deviation. Statistical analysis was performed using SPSS soft-
ware version 14.0 (SPSS, Inc., Chicago, IL, USA). The relative 
absorbance of the astrocytes and C6 glioma cells was analyzed 
by unpaired Student's t-test. For the positive expression rates of 
PGAM1 in astrocytoma tissues and peritumoral brain tissue, 
the χ2 test was used, and P<0.05 was considered to indicate a 
statistically significant difference.
Results
Expression of PGAM1 mRNA in C6 glioma cells and normal 
astrocytes. The RT-PCR PGAM1 products from astrocytes 
and C6 glioma were visualized by gel electrophoresis and the 
intensity of these bands was semi‑quantified (Fig. 1A and B). 
Using SPSS version 14.0 statistical software, 2 samples in trip-
licate (C6 glioma cells vs. normal astrocytes) were compared. 
It was identified that the expression of PGAM1 in C6 glioma 
cells (1.26±0.05) was significantly increased compared with 
that of normal astrocytes (0.75±0.07). The difference was 
statistically significant (P<0.05; Table I).
PGAM1 immunohistochemistry of astrocytoma and 
peritumoral brain tissue. A total of 8/11 (73.8%) peritumoral 
brain tissues were negative for PGAM1 (Fig. 2A and B). Only 3 
peritumoral brain tissues were positive for PGAM1 (3/11; 27.2%). 
In 102 cases of astrocytoma tissues, 74 cases (70.6%) were 
positive for PGAM1 and 28 cases were negative for PGAM1. 
There was a statistically significant difference in PGAM1 posi-
tive rates between the astrocytoma group and the peritumoral 
brain tissue group (χ2=8.35; P<0.01; Table II). The expression 
of PGAM1 in the low‑grade diffuse astrocytomas (WHO 
Grade II; Fig. 2C and D) and high‑grade astrocytomas (WHO 
Grade III‑IV; Fig. 3) was compared. PGAM1 was predominantly 
confined to the cytoplasm of tumor cells (Figs. 2 and 3). The 
results demonstrated that 18/38 (47.4%) cases of WHO Grade II 
astrocytoma were positive for PGAM1. A total of 54/64 cases 
(84.4%) of high-grade astrocytomas were positive for PGAM1. 
The PGAM1 positive rate was significantly different between 
Table I. Comparison of phosphoglycerate mutase 1 expression 
in C6 glioma cells and astrocytes.
  Expression quantity
Group No. of cases  (mean ± SD)
C6 glioma cells 30 1.26±0.05
Astrocytes 10 0.75±0.07
t=3.89, P<0.05. SD, standard deviation.
Table II. Comparison of phosphoglycerate mutase 1 protein in 
glioma tissue and peritumoral brain tissue.
 No. of   Positive
Group cases Negative Positive rate (%)
Normal brain tissue   11   8   3 27.2
Glioma tissue 102 30 72 70.6
χ2=8.35, P<0.01.
Table III. Association between phosphoglycerate mutase 1 
expression and the grades of gliomas.
 No. of   Positive
Group cases Negative Positive rate (%)
Grade II  38 20 18 47.4
Grade III‑IV 64 10 54 84.4
χ2=15.73, P<0.01.
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low‑grade astrocytomas (WHO grade II) and high‑grade astro-
cytomas (WHO grade III‑IV) (χ2=15.73; P<0.01; Table III).
Discussion
As one of the key enzymes in the glycolytic pathway, PGAM1 
primarily catalyzes the conversion of 3-phosphoglycerate into 
2-phosphoglycerate. PGAM1 may be in muscle-derived form 
(m-type) and brain-derived form (b-type) in mammals (6). 
B-type PGAM1 has been identified previously (7). Tumor 
cells are distinct from normal cells by their unique feature of 
the glucose metabolism: Tumor cells obtain energy primarily 
through the glycolysis pathway, whereas normal cells 
primarily metabolize glucose through aerobic oxidation (8). 
Figure 2. PGAM1 immunohistochemical staining in peritumoral brain tissue and diffuse astrocytoma (WHO grade II). (A) Hematoxylin and eosin stain of 
peritumoral brain tissue. Magnification, x400. (B) Peritumoral brain tissue is negative for PGAM1. Magnification, x400. (C) Hematoxylin and eosin stain 
demonstrates brain tissue infiltrated by mildly hypercellular glial cells with irregular and atypical nuclei and inconspicuous mitotic activity, diagnostic of 
diffuse astrocytoma (WHO grade II). Magnification, x200. (D) Diffuse astrocytoma is positive for PGAM1 with a cytoplasmic staining pattern. Magnification, 
x200. PGAM1, phosphoglycerate mutase 1.
Figure 1. PGAM1 mRNA expression level in C6 glioma cells and normal astrocytes. (A) Electrophoresis of PCR products of PGAM1. M, Marker; 1, Astrocytes; 
2, C6 glioma cells. (B) Semi‑quantitative analysis of PCR products of PGAM1 in C6 glioma cells and normal astrocytes. PGAM1, phosphoglycerate mutase 1; 
PCR, polymerase chain reaction.
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Bustamante et al (9) identify that the hexokinase activity is 
markedly low in normal tissue, whereas the activity of this 
enzyme in tumor cells is significantly increased. Previous 
studies have indicated that certain enzymes which inhibit 
glycolysis may effectively kill liver cancer cells and other 
cancer cells (10-12).
PGAM1 is the only enzyme in the glycolytic pathway 
that is regulated at the transcriptional level by the tumor 
suppressor gene p53 (13), In 2005, Evans et al (14) suggest 
that PGAM1 may be a novel target for cancer treatment. 
PGAM1 is significantly upregulated in 66.7% of hepatocel-
lular carcinomas, and markedly associated with the poorer 
survival of patients and poor differentiation of cancer 
cells (15). PGAM1 protein is overexpressed in breast cancer 
and prostate cancer (16,17). The expression of PGAM1 
is upregulated in esophageal cancer (18) and glioma 
cells (19,20). In the present study, PGAM1 is expressed in 
astrocytes and C6 glioma cells using RT-semi-quantitative 
PCR, but that the expression level in C6 glioma cells is 
significantly increased compared with that of astrocytes. 
Using immunohistochemical staining, it is identified 
that the level of PGAM1 protein in astrocytoma tissue is 
significantly increased compared with that in peritumoral 
brain tissue. Furthermore, high-grade astrocytomas exhibit 
higher levels of PGAM1 positivity compared with low-grade 
astrocytomas. Therefore, PGAM1 may play an important 
role in the tumorigenesis and progression of malignant 
gliomas. The results indicate that PGAM1 inhibitors may be 
potential anticancer drugs, but extensive future studies are 
required.
In summary, the expression of PGAM1 is upregulated in 
glioma cell lines and astrocytoma tissues. This suggests that 
PGAM1 may be involved in the tumorigenesis and progression 
of malignant gliomas. PGAM1 may become a novel target for 
glioma treatment in the future.
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